Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...

Alzheimer’s drug, donanemab (marketed as Kisunla), could be rejected for use by the National Health Service (NHS) in Britain, ...

New AI software promises to make diagnosing dementia quicker and more accurate, helping doctors provide timely and effective ...

But Eli Lilly got there first. With the FDA's approval in early July of Kisunla, its new medicine for Alzheimer's developed ...

Prescribing information for the two anti-amyloid Alzheimer's drugs currently available in the U.S. -- lecanemab (Leqembi) and ...

Boston University researchers developed an AI tool that accurately diagnoses 10 types of dementia, improving diagnosis ...

BU researchers created an algorithm capable of pinpointing causes of cognitive decline, using only patient information collected by physicians ...

Eli Lilly (NYSE: LLY) has been on a winning streak recently, with shares popping up by roughly 60% since the start of 2024 ...

The Alzheimer’s Association hailed the development ... Lilly has set a price of $32,000 per year for Kisunla, which is higher than the top-line price of $26,500 for Leqembi.

Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, ...

Both Leqembi and Kisunla have experimental data showing they can slow down the rate of increase in tau protein, revealing the close interaction between amyloid and tau in Alzheimer's pathology.

Lilly's success doesn't depend entirely on its obesity drug, though. Mounjaro, which is approved for type 2 diabetes, is the same drug under the hood as Zepbound and also has tremendous commercial ...